Sermorelin regulatory status
Current status of Sermorelin in the United States: Former FDA approval (Geref). In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of Sermorelin?
- FDA and compounding
- There is no currently marketed sermorelin product in the United States. FDA approved Geref (sermorelin acetate) under NDA 19-863 in 1990 and NDA 20-443 in 1997. The sponsor discontinued both in 2008, and FDA withdrew the approvals effective June 18, 2009. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness. Sermorelin is not on the 503A bulks list and does not appear in any 503A nomination category or on FDA's withdrawn list. Many 503A pharmacies compound it on the basis that it is a component of a previously approved drug. FDA's 503B nomination list places sermorelin acetate in Category 1 and marks it as a component of FDA approved drugs. FDA has not issued a 503A-specific ruling on it, so check with the dispensing pharmacy on the basis it relies on. Using sermorelin for adult anti-aging, fat loss or sleep is an unapproved use.
- WADA
- WADA prohibited
- Access path
- Prescription from a licensed provider filled by a state licensed 503A compounding pharmacy, commonly through telehealth clinics.
- No FDA approved product is currently marketed (Geref was withdrawn in 2009).
- Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.
Full Sermorelin page: evidence, dosing in the literature, and sources
How has the status of Sermorelin changed over time?
- WADA
WADA publishes the 2027 Prohibited List
WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.
- WADA
WADA 2026 Prohibited List takes effect
The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.
- WADA
WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times
The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 and its derivatives, including TB-500, and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Sermorelin and the source of each dated event.
- [1]Federal Register, March 4, 2013: Determination that Geref (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness (NDA 19-863 and NDA 20-443)Federal Register, 2013
- [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (503A bulks list, Category 1, 2, and 3 lists)FDA, 2026
- [3]WADA Prohibited List, section S2 (growth hormone releasing hormone and its analogues, including sermorelin)WADA, 2026
- [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [5]WADA 2027 Prohibited ListWADA, 2026
From the blog
- Sermorelin vs HGH: mechanism, evidence, and legal status
Sermorelin signals the pituitary to release growth hormone; HGH (somatropin) is the hormone itself. Only somatropin is FDA approved today, and anti-aging use of either is off-label.
- Tesamorelin vs sermorelin vs ipamorelin: evidence and legality
Tesamorelin, sermorelin, and ipamorelin compared in one table: mechanism, FDA approval, compounding status, human evidence, and WADA status, with links to each pairwise comparison.